alcohol brands

335 registered brands containing alcohol in Tanzania.

Alcohol 2D chemical structure

2D structure

Alcohol

PubChem CID 702

Molecular formula: C2H6O

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate. The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes. ... Ethanol is known to affect a large number of membrane proteins that participate in signaling pathways such as neurotransmitter receptors, enzymes, and ion channels, and there is extensive evidence that ethanol interacts with a variety of neurotransmitters. The major actions of ethanol involve enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABAa receptors and blockade of the N-methyl-D-aspartate (NMDA) subtype of glutamate, an excitatory amine acid (EAA) receptor. Animal studies indicate that the acute effects of ethanol result from competitive inhibition of glycine binding to NMDA receptor and disruption of glutamatergic neurotransmission by inhibiting the response of the NMDA receptor. Persistent glycine antagonism and attenuation of glutamatergic neurotransmission by chronic ethanol exposure results in tolerance to ethanol by enhancing EAA neurotransmission and NMDA receptor upregulation. The latter appears to involve selective increases in NMDA R2B subunit concentrations and other molecular changes in specific brain loci. The abrupt withdrawal of ethanol thus produces a hyperexcitable state that leads to the ethanol withdrawal syndrome and excitotoxic neuronal death. GABA-mediated inhibition, which normally acts to limit excitation, is eliminated during ethanol withdrawal syndrome and further intensifies this excitation. In addition, NMDA receptors function to inhibit the release of dopamine in the nucleus accumbens and mesolimbic structures, which modulate the reinforcing action of addictive xenobiotics such as ethanol. By inhibiting NMDA receptor activity, ethanol could increase dopamine release from the nucleus accumbens and ventral tegmental area and could thus create dependence. Chronic ethanol administration also results in tolerance, dependence, and an ethanol withdrawal syndrome, mediated, in part, by desensitization and or downregulation of GABAa receptors. The development of alcoholic ketoacidosis (AKA) requires that a combination of physical and physiologic events occur. The normal response to starvation and depletion of hepatic glycogen stores is for amino acids to be converted to pyruvate. Pyruvate can serve as a substrate for gluconeogenesis, be converted to acetyl-CoA, which can enter the Krebs cycle or can be utilized in various biosynthetic pathways (eg, fatty acid, ketone bodies, cholesterol, and acetylcholine) ... Ethanol metabolism generates NADH, resulting in an excess of reducing potential. This high redox state favors the conversion of pyruvate to lactate, diverting pyruvate from being a substrate for gluconeogenesis. To compensate for the lack of normal metabolic substrates, the body mobilizes fat from adipose tissue and increased fatty acid metabolism as an alternative source of energy. This response is mediated by a decrease in insulin and an increased secretion of glucagon, catecholamines, growth hormone, and cortisol. Fatty acid metabolism results in the formation of acetyl-CoA and it combines with the excess acetate that is generated from ethanol metabolism to form acetoacetate. Most of the acetoacetate is reduced to beta-hydroxybutyrate due to the excess reducing potential or high redox state of the cell. Volume depletion interferes with the renal elimination of acetoacetate and beta-hydroxybutyrate, and contributes to the acidosis. An elevated lactate concentration may result from shunting from pyruvate or

Source: PubChem (NCBI) · compound 702

Product Manufacturer Status Country
Furozyd
Solution for Injection
Zenex Animal Health Registered/Compliant Tanzania
FUSIBRAN
Cream
Brawn Laboratories Registered/Compliant Tanzania
FUZI-SK
Topical Solution
S Kant Healthcare Registered/Compliant Tanzania
GENIX 400
Tablets
Scott-edil Registered/Compliant Tanzania
Genta-100
Solution for injection
Interchemie Werken ''de Adelaar'' B.v Registered/Compliant Tanzania
GEODERM Cream
Cream
Kremoint Pharma Registered/Compliant Tanzania
GERMISEP 2.5g Tablets Hovid Registered/Compliant Tanzania
GLIMREA 1 TABLETS
Uncoated Tablets
Bafna Pharmaceuticals Registered/Compliant Tanzania
GLIMREA 2 TABLETS
Uncoated Tablets
Bafna Pharmaceuticals Registered/Compliant Tanzania
GO GEL
Gel
S Kant Healthcare Registered/Compliant Tanzania
GYNO-DAKTAZOL OVULES
Vaginal Pessaries
Jerusalem Pharmaceuticals Registered/Compliant Tanzania
HEKOCEFI-200
Oral tablet
East African Overseas Registered/Compliant Tanzania
HEKOCET -10
Film Coated Tablet
East African Overseas Registered/Compliant Tanzania
HEKOFEN -400
Oral tablet
East African Overseas Registered/Compliant Tanzania
HEKOGYL-200
Oral tablet
East African Overseas Registered/Compliant Tanzania
HEKOVAST-20
Oral tablet
East African Overseas Registered/Compliant Tanzania
HELETIN 100
Capsules
Annora Pharma Registered/Compliant Tanzania
HELETIN 150
Capsules
Annora Pharma Registered/Compliant Tanzania
HEPALIN
Solution for injection
Lincoln Parenteral Registered/Compliant Tanzania
HEPARIN INJECTION BP
Solution for Injection
Gland Pharma Registered/Compliant Tanzania
HERPORIG
Ointment
Next Wave Registered/Compliant Tanzania
HETSOLID 110
capsule
Hetero Labs Registered/Compliant Tanzania
HETSOLID 150
capsule
Hetero Labs Registered/Compliant Tanzania
HETSOLID 75
capsule
Hetero Labs Registered/Compliant Tanzania
Hexigold Hand Rub G. S. Pharmbutor Registered/Compliant Tanzania
Hexigold Hospital Concentrate G. S. Pharmbutor Registered/Compliant Tanzania
HYCLIN 20
Solution
Imaec Registered/Compliant Tanzania
Hydraline 25
Tablets
Macleods Pharmaceuticals Registered/Compliant Tanzania
HYDRAZOLE
Cream
Atco Laboratories Registered/Compliant Tanzania
HYDROKANT
Cream
S Kant Healthcare Registered/Compliant Tanzania
HYDROMAX
Cream
Kremoint Pharma Registered/Compliant Tanzania
Hyoscine Butylbromide
Tablets
Medopharm Registered/Compliant Tanzania
Imatinib Mesylate
Film coated tablets
Shilpa Medicare Limited Registered/Compliant Tanzania
Infen 25
Tablets
Emcure Pharmaceuticals Registered/Compliant Tanzania
Injectiphos
Solution for injection
Zenex Animal Health Registered/Compliant Tanzania
INSTANT HAND SANITIZER GEL
Solution
Ecolab Registered/Compliant Tanzania
Iotim
Ophthalmic Solution
Fdc Registered/Compliant Tanzania
Iotim 0.5 % w/v
Ophthalmic Solution
Fdc Registered/Compliant Tanzania
Irda 150 mg
Film Coated Tablet
Nobel Ilac Registered/Compliant Tanzania
Irda 300 mg
Film Coated Tablet
Nobel Ilac Registered/Compliant Tanzania
Isoniazid Dispersible Tablets 100mg
Dispersible Tablets
Oxalis Labs Registered/Compliant Tanzania
JBCOSE-MAX 1000 & 100
Tablets
Unique Pharmaceutical Laboratories Registered/Compliant Tanzania
JBCOSE-MAX 500 & 50
Tablets
Unique Pharmaceutical Laboratories Registered/Compliant Tanzania
JUVETA ER 25
Extended Release Tablet
Inventia Healthcare Registered/Compliant Tanzania
JUVETA ER-50
Film coated tablets
Inventia Healthcare Registered/Compliant Tanzania
KARAMOL-KP ORAL SOLUTION
Solution, Oral
Katwaza Pharmaceuticals Industry Ltd Registered/Compliant Tanzania
KETOMUSC 2.5
Gel
Gopaldas Visram Registered/Compliant Tanzania
KETONEM Cream
Cream
Nem Laboratories Registered/Compliant Tanzania
KETOVATE CREAM
Cream
Bal Pharma Registered/Compliant Tanzania
KEZORAL
Cream
Dawa Registered/Compliant Tanzania
23456